
Casma takes a new therapeutic approach to neurodegeneration
Casma Therapeutics has nominated its first development candidate, CSM-101, a first-in-class TRPML1 agonist, marking a new therapeutic approach for targeting lysosomal dysfunction in genetically driven neurodegenerative diseases. CSM-101 is being developed for the treatment of Gaucher’s disease patients with Parkinson’s disease (GD-PD), with the potential to expand… Read More














